Probiotic Research in Therapeutics
117,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 6-10 Tagen
payback
59 °P sammeln
  • Gebundenes Buch

Humans have numerous microorganisms residing in the body, especially in the gut, far exceeding the human body's normal mammalian cells. Recent research links the gut microbiome, the population of microorganisms living in the gastrointestinal tract, with brain diseases. This volume explores the concept and possibility of its extension to manage a galaxy of CNS diseases, including Parkinson's, Alzheimer's, Autism spectrum disorders, depression, insomnia, and chronic fatigue syndrome. This volume elaborates about communication channels between gut and brain via the vagus nerve, short-chain fatty…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Humans have numerous microorganisms residing in the body, especially in the gut, far exceeding the human body's normal mammalian cells. Recent research links the gut microbiome, the population of microorganisms living in the gastrointestinal tract, with brain diseases. This volume explores the concept and possibility of its extension to manage a galaxy of CNS diseases, including Parkinson's, Alzheimer's, Autism spectrum disorders, depression, insomnia, and chronic fatigue syndrome. This volume elaborates about communication channels between gut and brain via the vagus nerve, short-chain fatty acids including omega acids, and other inflammasomes.
In contrast to the available books on the topic, this title is more versatile and endeavors to bring together scientific pre-clinical, and clinical claims on the probable psychobiotic implication of probiotic therapy. The book will appeal similar to the general public, students, experienced researchers, and academicians. It is endeavored to address an aspect of probiotic usage beyond gut disorders. We hope that it would be helpful to people studying the human nervous system and related conditions with their treatments.
Autorenporträt
Dr. Indu Pal Kaur is a professor of Pharmaceutics and currently the Chairperson at the University Institute of Pharmaceutical Sciences (UIPS), Panjab University, Chandigarh, India. Her research forte enhances the performance of drugs, including small and large biomolecules, viz. probiotics using active-tailored delivery systems. The emphasis of her work lies in Industrial and clinical translation, as evidenced by four technologies transferred by her group to the Industry. She has 145 high-impact publications, 21 book chapters, four books, and 4 Journal special issues to her credit. She is on the Editorial and Review Board of more than 50 journals.  Dr. Parneet Kaur Deol is presently working as Assistant Professor at G.H.G. Khalsa College of Pharmacy Gurusar Sadhar Ludhiana, Punjab, India. She has more than ten years of experience in probiotic research and has published her work in highly reputed peer-reviewed international journals. She has co-edited a particular issue for 'Current Pharmaceutical Design' with Prof. Indu Pal Kaur in 2019. Dr. Deol has presented her work at various national and international platforms. She has contributed 21 international publications to her credit, with a cumulative impact of more than 50.  Dr. Simarjot Kaur Sandhu is presently working as an analytical chemist at Taro Pharmaceutical Industries Ltd. Brampton, Ontario, Canada. She has done her doctorate from the Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India. Her area of research lies in improving the profile of phytopharmaceuticals and probiotics by encapsulating them within nanoparticles. She has published six international publications and has filed two India Patent Applications and one European and one US patent application out of her Ph.D. work.